EQT Life Sciences
EQT · Venture capital
RollingLast verified 7 Nov 2026
EQT Life Sciences is a major European venture capital investor providing capital and hands-on guidance to companies developing treatments and technologies in healthcare, biotechnology, and dementia.
14 deals in the last 24 months, latest 1 Sep 2026. Derived from its deals in the news.
Key facts
- Stages
- Series A, Series C+
- Sectors
- Biotech & pharma, Healthtech, Medtech
- Typical round size
- €143.3M (median of its recent deals, not a ticket)
- Leads rounds
- 50% of recent deals with a known role
- Eligible countries
- Not stated
- Provider based in
- Sweden
- Timing
- Rolling applications
- Focus
- life sciences; biotech; health economics; dementia treatments
- How to apply
- Apply route unknown
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| Mistral AI | Series C+ | AI & machine learning | €3B | lead | 1 Sep 2026 |
| Lovable | Series C+ | €343M | lead | 12 Aug 2026 | |
| ICEYE | Series C+ | Space, Defence & security | €1B | lead | 5 Aug 2026 |
| Syntetica | Series A | Circular economy, Materials & chemistry, Cleantech | €26.9M | participant | 4 Aug 2026 |
| Mews | Series C+ | Travel & hospitality, B2B SaaS, AI & machine learning | €268.7M | lead | 23 Jan 2026 |
| Parloa | Series C+ | AI & machine learning, B2B SaaS | €313.5M | participant | 15 Jan 2026 |
| Lovable | Unknown | AI & machine learning, B2B SaaS | €295.6M | participant | 19 Dec 2025 |
| Payrails | Series A | Fintech, B2B SaaS | €28.7M | participant | 11 Jun 2025 |
| IFS · Sweden | Unknown | AI & machine learning, B2B SaaS, Industrial & manufacturing | – | lead | 10 Apr 2025 |
| Peak3 | Series A | Insurtech | €31.3M | lead | 28 Mar 2025 |
| evroc | Series A | AI & machine learning, Hardware & IoT | €50M | participant | 20 Mar 2025 |
| Biolevate | Seed | Healthtech, Biotech & pharma, AI & machine learning | €6M | lead | 26 Nov 2024 |
| Candela · Sweden | Series C+ | Mobility, Climate & energy, Cleantech | €13.3M | participant | 22 Nov 2024 |
| The Exploration Company | Series B | Space | €143.3M | participant | 18 Nov 2024 |
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
One of Europe's Largest and Most Experienced Life Sciences Investors
https://eqtgroup.com/private-capital/eqt-life-sciences - Sectors
ideas that have the potential to improve patients' lives. We contribute not only capital, but also strategic, clinical, operational, financial, and commercial…
https://eqtgroup.com/private-capital/eqt-life-sciences
Status history
- 7 Nov 2026: Uncertain → Rolling (profiles: investor activity)
- 7 Nov 2026: Rolling → Uncertain (freshness: investor activity)
- 6 Nov 2026: Rolling (first extraction)
Something wrong or out of date? Report an error.
Work at EQT? Claim this profile to confirm what you invest in.